Similar needs exist in patients with high-risk ER+/HER2− tumours, who are currently offered extended adjuvant endocrine therapy plus CDK4/6 inhibitors, with no possibility of de-escalation in patients with favourable prognosis based on their response to NACT. The gene discussed is ESR1; the disease is neoplasm.